DEF 14A: Bio-Rad Laboratories Announces 2024 Annual Meeting and Amended Incentive Award Plan

Bio-Rad Laboratories is set to hold its annual stockholder meeting on April 23, 2024, to vote on director elections, auditor ratification, and approval of an amended incentive award plan.

Summary

• Bio-Rad Laboratories will hold its 2024 annual meeting of stockholders on April 23, 2024, at its corporate offices in Hercules, California.
• Stockholders will vote on the election of two Class A and four Class B directors, the ratification of KPMG LLP as independent auditors, and the approval of the amended 2017 Incentive Award Plan.
• The record date for determining stockholders eligible to vote is February 26, 2024.
• The proxy statement and annual report are available online, and proxy cards are being distributed on or about March 27, 2024.
• The board recommends voting 'FOR' all director nominees, the ratification of auditors, and the approval of the amended incentive award plan.
• The amended 2017 Incentive Award Plan includes provisions for non-employee director participation, extends the plan's expiration date to February 9, 2034, and removes outdated clauses related to Section 162(m) of the Internal Revenue Code.
• The company is not seeking to increase the shares available for issuance under the Equity Plan.
• As of February 26, 2024, there were 80,895 shares subject to outstanding options, 337,058 shares subject to outstanding RSUs, 8,381 shares subject to outstanding PSUs (assuming target performance level), and 1,140,669 shares remaining available for future awards under the Equity Plan.
• The company's three-year average burn rate is 0.52% of fully diluted weighted-average common shares outstanding.
• The company estimates that the shares reserved for issuance under the Equity Plan would be sufficient for approximately 4 to 5 years of awards.
• The company's end of year overhang rate was 5.49% in 2023, 5.69% in 2022, and 6.0% in 2021.
• If the Equity Plan is approved, the company expects its overhang at the end of 2024 will be approximately 4.98%.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The proposed changes to the incentive award plan could be viewed positively by investors who believe that they will better align executive compensation with company performance.

Positives

• The amended 2017 Incentive Award Plan includes provisions for non-employee director participation, potentially aligning their interests more closely with shareholders.
• The company's equity plan incorporates governance best practices, such as conservative share counting and a prohibition on repricing options without stockholder approval.
• The company's three-year average burn rate is 0.52% of fully diluted weighted-average common shares outstanding.
• The company estimates that the shares reserved for issuance under the Equity Plan would be sufficient for approximately 4 to 5 years of awards.
• The company's end of year overhang rate was 5.49% in 2023, 5.69% in 2022, and 6.0% in 2021.
• If the Equity Plan is approved, the company expects its overhang at the end of 2024 will be approximately 4.98%.

Risks

• Failure to obtain stockholder approval for the amended incentive award plan could limit the company's ability to attract and retain key personnel.
• The Schwartz family's control of the company could lead to decisions that benefit the family at the expense of other stockholders.
• The company's reliance on a small group of key executives could create a risk if one or more of those executives were to leave the company.

Future Outlook

The company anticipates that the shares reserved for issuance under the Equity Plan will be sufficient for approximately 4 to 5 years of awards, assuming consistent grant practices.

Industry Context

This announcement is typical for publicly traded companies as they prepare for their annual meetings and seek stockholder approval for key governance and compensation matters. The proposed changes to the incentive award plan are likely aimed at aligning executive compensation with company performance and attracting/retaining talent in a competitive market.

Comparison to Industry Standards

• The peer group used for compensation benchmarking includes companies like Agilent Technologies, Mettler-Toledo International, and Waters Corporation, which are all recognized players in the life sciences and medical products industries.
• The company's three-year average burn rate of 0.52% is within a reasonable range compared to industry benchmarks for equity compensation plans.
• The company's end of year overhang rate of 5.49% is within a reasonable range compared to industry benchmarks for equity compensation plans.

Stakeholder Impact

• Approval of the amended incentive award plan could impact stakeholders by potentially aligning executive compensation with company performance, which could lead to increased shareholder value.
• The election of directors will determine the composition of the board, which oversees the company's strategy and operations.
• The ratification of auditors ensures the integrity of the company's financial statements.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold its annual meeting on April 23, 2024.
• The company will implement the amended incentive award plan if it is approved by stockholders.

Key Dates

Keywords

Bio-Rad Laboratories, annual meeting, proxy statement, directors, auditors, incentive award plan, executive compensation, stockholders, KPMG, equity plan